Dermatology News

Patients with psoriatic arthritis treated with bimekizumab demonstrated improvements across joint and skin parameters compared with placebo, according to Phase 3 clinical trial data presented at the EULAR 2022 Congress.

A two-dose vaccine course is “highly effective” against COVID-19 infection and severe outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease, according to data.

AVT04, a biosimilar candidate to ustekinumab developed by Alvotech, met the primary endpoint in a confirmatory clinical study of patients with chronic plaque-type psoriasis, according to a company press.

The FDA has approved Vtama cream for the treatment of plaque psoriasis in patients with mild, moderate or severe disease, Dermavant Sciences announced.

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.

Clinical trials for psoriatic arthritis therapies should place a greater focus on using deeper states of remission as primary and co-primary endpoints, according to speakers at the FDA & American College of Rheumatology Virtual Summit.

Rheumatologists are likely to be at the “forefront” of diagnosing scleroderma skin disorders and other dermatological conditions, a speaker said at Congress of Clinical Rheumatology East.

DESTIN, Fla. — Hydroxychloroquine may no longer be the optimal treatment option for systemic dermatomyositis, according to data presented at the Congress of Clinical Rheumatology East.

DESTIN, Fla. — An ever-increasing array of treatment options is allowing rheumatologists to target specific disease domains in their patients with psoriatic arthritis, according to a speaker at the Congress of Clinical Rheumatology East.

Ixekizumab demonstrates a safety and tolerability profile that is “reassuring” and consistent with previous studies in patients with psoriatic arthritis, according to researchers.